EVALUATE EFFICACY OF AVONEX &SECONDARY MULTIPLE SCLEROSIS

$48,578M01FY2000RRNIH

Ohio State University, Columbus OH

Investigators

Linked publications & trials

Paper 36462295 Paper 34473669 Paper 33002231 Paper 31505070 Paper 31404238 Paper 31134052 Paper 30804020 Paper 30504071 Paper 29927798 Paper 28724164 Paper 28325061 Paper 27824768 Paper 27411977 Paper 27410922 Paper 27210023 Paper 27174555 Paper 27054932 Paper 26938509 Paper 26262903 Paper 26237484 Paper 26071920 Paper 26036953 Paper 25874884 Paper 25594222 Paper 25556571 Paper 25414152 Paper 24839145 Paper 24726195 Paper 24636665 Paper 24607755 Paper 24533206 Paper 24530820 Paper 23957903 Paper 23880114 Paper 23856854 Paper 23812458 Paper 23307944 Paper 23271384 Paper 23148814 Paper 23147078 Paper 23090528 Paper 23076979 Paper 23076798 Paper 22843347 Paper 22774383 Paper 22746258 Paper 22739802 Paper 22640930 Paper 22609018 Paper 22542118 Paper 22360694 Paper 22124213 Paper 22098224 Paper 22089885 Paper 21600570 Paper 21513606 Paper 21504886 Paper 21422852 Paper 21349614 Paper 21309194 Paper 21295383 Paper 21233301 Paper 21071279 Paper 20963843 Paper 20827170 Paper 20808854 Paper 20737553 Paper 20672296 Paper 20496988 Paper 20471092 Paper 20415603 Paper 20335550 Paper 20204490 Paper 20190643 Paper 20178389 Paper 20166790 Paper 20144509 Paper 20142026 Paper 20064902 Paper 20051282 Paper 20043337 Paper 19959695 Paper 19802320 Paper 19797280 Paper 19751089 Paper 19622708 Paper 19535429 Paper 19464358 Paper 19450044 Paper 19447923 Paper 19420195 Paper 19272714 Paper 19258033 Paper 19241490 Paper 19192424 Paper 19185635 Paper 19150180 Paper 19125177 Paper 19047802 Paper 19037811

Abstract

The primary objective of this study is to determine whether weekly intramuscular treatment with AVONEX (interferon beta-1a) when compared to placebo, is effective in slowing progression of secondary progressive multiple sclerosis (MS), as determined by a composite outcome measure consisting of the Time 25-foot Walk, Nine-Hold (9HPT), and Paced Auditory Serial Addition Test 3 (PASAT 3).

View original record on NIH RePORTER →